Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027066 (myoclonus)
 4,275 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The relationship of DDT myoclonus and antimyoclonic agents to the concentration of cGMP in the cerebellum was investigated. Intragastric administration of 600 mg/kg DDT increased mouse cerebellar cGMP levels about 4 fold. Antimyoclonic agents, such as L-5HTP plus fluoxetine, clonazepam, phenoxybenzamine, prostaglandin E2 and harmaline, all counteracted the elevation of cerebellar cGMP induced by DDT. Cinnanserin, a 5-HT receptor blocker, did not counteract the reduction of cerebellar cGMP produced by L-5HTP plus fluoxetine, clonazepam, and phenoxybenzamine, although cinnanserin abolished the antimyoclonic actions of these agents. Destruction of the inferior olive-climbing fiber pathway by 3-acetylpyridine in rats did not prevent the elevation of cerebellar cGMP levels by DDT. L-5HTP, clonazepam and phenoxybenzamine still significantly counteracted DDT-induced elevation of cerebellar cGMP levels in the inferior olive lesioned rats, although these agents no longer had any antimyoclonic action in these animals. These data indicate that 1) DDT-induced elevation of cerebellar cGMP and DDT-induced myoclonus are not related, and 2) antimyoclonic agents counteract DDT-induced elevation of cerebellar cGMP levels via pathways other than the olivo-cerebellar tract.
 ...
PMID:Cerebellar cyclic GMP in p,p'-DDT myoclonus: effects of antimyoclonic agents. 630 46

Intragastric injection of the insecticide DDT produces a stimulus-sensitive myoclonus in mice and rats. Unilateral stereotaxic infusions of DDT into rat medullary reticular formation also induced generalized myoclonus, identical to that produced by systemic administration. Similar myoclonus, but of lesser intensity, occurred when DDT was injected into cerebellar nuclei, red nucleus, and the inferior olive. Multiple other regions of the brain were resistant to the myoclonic action of locally infused DDT. Direct infusions into the medullary reticular formation of allethrin, which has a similar action on neuronal membranes as DDT, or the glycine receptor antagonist, strychnine, also elicited myoclonus.
 ...
PMID:DDT myoclonus: sites and mechanism of action. 637 51

Possible involvement of prostaglandins (PG) in the antimyoclonic action of clonazepam was examined in the p,p'-DDT-animal model of myoclonus. PG synthesis inhibitors and the PG antagonist polyphloretin phosphate (PPP) counteracted the antimyoclonic action of clonazepam in mice. PGE2 reduced DDT-induced myoclonus; this effect was blocked by PPP. Another antimyoclonic drug combination, L-5-hydroxytryptophan plus chlorimipramine, was not blocked by PPP or indomethacin. The antimyoclonic action of clonazepam may be mediated by enhancement of PG synthesis.
 ...
PMID:Role of prostaglandins in the antimyoclonic action of clonazepam. 723 84

The effects of 3-acetylpyridine (3-AP), which destroys the inferior olive, and harmaline, which stimulates inferior olive-climbing fiber activity, on DDT-induced myoclonus, wee studied in rats. 3-AP shortened and harmaline delayed the time of onset of myoclonus after intragastric administration of DDT. 3-AP also counteracted the antimyoclonic action of L-5-hydroxytryptophan plus chlorimipramine, clonazepam and phenoxybenzamine in this animal model. The results suggest that these antimyoclonic agents require an intact olivocerebellar pathway for their action.
 ...
PMID:Relationship of inferior olive-climbing fibers to p,p'-DDT-induced myoclonus in rats. 726 34

An abnormality of serotonergic neurotransmission has been hypothesized in p,p'-DDT intoxication to explain myoclonus and the antimyoclonic properties of 5-hydroxytryptophan (5-HTP). To study the role of serotonin (5-HT) receptors in myoclonus induced by p,p'-DDT in the rat, we performed time-course and dose-response studies of the effects of p,p'-DDT on behavior and regional 5-HT1 and 5-HT2 binding sites. At a time when low dose (80 mg/kg) p,p'-DDT elicited stimulus-sensitive and spontaneous myoclonus, there were no significant changes in Bmax or Kd of 5-HT1A, 5-HT1B, 5-HT1C sites in cortex, striatum, brainstem or spinal cord, agonist- or antagonist-labelled 5-HT2 sites in cortex, or 5-HT uptake sites. High dose p,p'-DDT (1000 but not 500 mg/kg), which also induced convulsions, only slightly increased 5-HT1 (unsubtyped) binding sites in cortex but not in brainstem or spinal cord and had no effect on antagonist-labelled 5-HT2 sites. In naive frontal cortex in vitro, 1 microM p,p'-DDT displaced neither [3H]5-HT or [3H]ketanserin specific binding. Lesions of central indoleamine neurons made with 5,7-dihydroxytryptamine significantly prolonged the latency and attenuated the severity of p,p'-DDT behavioral abnormalities, increasing the dose of p,p'-DDT which induced myoclonus (MD50) or convulsions (CD50) in 50 percent of the rats. This is the first report of 5,7-DHT-induced attenuation in the p,p'-DDT myoclonic model.
 ...
PMID:p,p'-DDT myoclonic/epileptic model: serotonin receptor binding and behavioral studies in the rat. 799 Dec 14

The antimyoclonic property of the novel antiepileptic drug, gabapentin (1-(aminomethyl) cyclohexane acetic acid), was tested in cardiac arrest-and p,p'-DDT(1,1,1-trichloro-2,2-bis (p-chlorophenyl)ethane)-induced animal models of myoclonus. Gabapentin dose-dependently attenuated myoclonus in posthypoxic rats for more than 3 h. The drug was also found to be effective in controlling the early stages of seizures following the anoxic insult. In contrast, the drug was ineffective in controlling either myoclonus or seizures in p,p'-DDT-treated animals. These results suggest that gabapentin can be used used as an effective therapeutic agent in an acute hypoxia/ischemia-induced neurological disorder. The data further indicate that distinct neurological mechanisms may be operating in the expression of myoclonus among posthypoxic and p,p'-DDT-induced animal models.
 ...
PMID:Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus. 866 53

This is a comprehensive review of animal models of myoclonus with particular emphasis on posthypoxic myoclonus and other newer chemically induced models. A stimulus-sensitive myoclonus was developed by experimentally inducing cardiac arrest in rats. The etiology, pharmacology, and neurochemistry associated with this model are consistent with posthypoxic myoclonus in humans. The complex etiology of posthypoxic myoclonus and the effectiveness of diverse pharmacological therapies in this movement disorder suggest that multiple interactive neurological mechanisms are operative. The p,p'-DDT-induced animal model of myoclonus differs from posthypoxic myoclonus in terms of its neurochemical and pathophysiological mechanisms. Also, micro-injection of compounds that modulate specific neurotransmitter systems in select brain regions induces myoclonus in normal animals, suggesting that these chemically induced models may be useful in understanding the intricate neurochemical and neuroanatomical mechanisms associated with myoclonus. The experimental evidence demonstrates that these novel animal models of myoclonus have salient neurological characteristics, reasonable predictability of novel antimyoclonic agents, and pathophysiological similarities to the disorder in humans. Thus, these animal models of myoclonus have the potential to provide us with valuable information about the disorder that is not readily obtainable by other means.
 ...
PMID:Animal models of myoclonus. 889 97

In the IPCS Collaborative Study on Neurobehavioral Screening Methods, the "Top Dose" (TD) of p,p'-DDT (oral gavage, in corn oil) was determined to be different depending on the volume of administration: TD = 87 mg/kg when delivered in 1 ml/kg (i.e., 87 mg/ml) vs. TD = 130.5 mg/kg when given at 5 ml/kg (26.1 mg/ml). Two acute dose-response studies were conducted, the only difference being the doses used (pre-established percentages of the TD) and dosing volume (1 and 5 ml/kg); a third study was conducted using a single dose and varying the dosing volume (1 and 5 ml/kg). In the higher-volume study, dose-response curves for almost all the affected endpoints were shifted to the right, and the effects of the highest dose were less severe compared to the lower-volume study. For example, tremors were observed in all rats dosed with 43.5 mg/kg at 1 ml/kg, but only in 40% of the dose group given 65.3 mg/kg at 5 ml/kg. The highest dose groups (100% TD) showed myoclonus in both studies, but the incidence was 100% at 87 mg/kg (1 ml/kg) compared to 60% at 130.5 mg/kg (5 ml/kg). The dose-response curves indicated that the effective doses were generally 2-5 times higher, i.e., less potent, using a volume of 5 ml/kg. In general, the profiles of effect were similar in that the Sensorimotor and Convulsive domains were significantly altered in both studies, but again the dose-response curves were shifted; these domains were affected by both 43.5 and 87 mg/kg at 1 ml/kg, but only by 130.5 mg/kg at 5 ml/kg. The Neuromuscular domain, however, was only affected in the 1 ml/kg study (at 87 mg/kg). These differences in outcome could be due to higher partitioning of DDT into the oil, or increased gut motility, both of which could be due to the larger volume of oil delivered. The findings illustrate the importance of knowing the pharmacokinetic properties of the compound in question, as well as standardization of such variables whenever direct comparisons of dose levels are conducted.
 ...
PMID:The influence of dosing volume on the toxicity of p,p'-DDT. 945 36

Myoclonus can be classified as physiologic, essential, epileptic, and symptomatic. Animal models of myoclonus include DDT and posthypoxic myoclonus in the rat. 5-Hydrotryptophan, clonazepam, and valproic acid suppress myoclonus induced by posthypoxia. The diagnostic evaluation of myoclonus is complex and involves an extensive work-up including basic electrolytes, glucose, renal and hepatic function tests, paraneoplastic antibodies, drug and toxicology screens, thyroid antibody and function studies, neurophysiology testing, imaging, and tests for malabsorption disorders, assays for enzyme deficiencies, tissue biopsy, copper studies, alpha-fetoprotein, cytogenetic analysis, radiosensitivity DNA synthesis, genetic testing for inherited disorders, and mitochondrial function studies. Treatment of myoclonus is targeted to the underlying disorder. If myoclonus physiology cannot be demonstrated, treatment should be aimed at the common pattern of symptoms. If the diagnosis is not known, treatment could be directed empirically at cortical myoclonus as the most common physiology. In cortical myoclonus, the most effective drugs are sodium valproic acid, clonazepam, levetiracetam, and piracetam. For cortical-subcortical myoclonus, valproic acid is the drug of choice. Here, lamotrigine can be used either alone or in combination with valproic acid. Ethosuximide, levetiracetam, or zonisamide can also be used as adjunct therapy with valproic acid. A ketogenic diet can be considered if everything else fails. Subcortical-nonsegmental myoclonus may respond to clonazepam and deep-brain stimulation. Rituximab, adrenocorticotropic hormone, high-dose dexamethasone pulse, or plasmapheresis have been reported to improve opsoclonus myoclonus syndrome. Reticular reflex myoclonus can be treated with clonazepam, diazepam and 5-hydrotryptophan. For palatal myoclonus, a variety of drugs have been used.
 ...
PMID:Myoclonus. 2149 98


<< Previous 1 2